CLARITY PHARMACEUTICALS LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.22 AUD | -2.61% |
|
+0.58% | +174.74% |
| Jun. 07 | Clarity Pharmaceuticals Confirms Isotope Supply Continuity for Clinical Trials | MT |
| May. 30 | Clarity Pharmaceuticals Signs Supply Deal for Copper Isotope | MT |
Valuation
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 131.5 | 182.5 | 1,626 | - | - |
| Enterprise Value (EV) 1 | 76.21 | 117.4 | 1,495 | 1,537 | 1,502 |
| P/E ratio | -5.31 x | -7.37 x | -42.2 x | -32.5 x | 279 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 20.1 x | - | - | - | 24.7 x |
| EV / Revenue | 11.6 x | - | - | - | 22.8 x |
| EV / EBITDA | -3.22 x | -4.81 x | -39.1 x | -30.3 x | 68.4 x |
| EV / FCF | -5.63 x | -4.26 x | -44.1 x | -31.2 x | 35.6 x |
| FCF Yield | -17.7% | -23.5% | -2.27% | -3.21% | 2.81% |
| Price to Book | 1.37 x | 2.64 x | 10.1 x | 15.5 x | 13.1 x |
| Nbr of stocks (in thousands) | 257,939 | 260,663 | 311,454 | - | - |
| Reference price 2 | 0.5100 | 0.7000 | 5.220 | 5.220 | 5.220 |
| Announcement Date | 8/24/22 | 8/24/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 6.554 | - | - | - | 65.9 |
| EBITDA 1 | - | -23.69 | -24.4 | -38.27 | -50.63 | 21.97 |
| EBIT 1 | - | -23.74 | -24.5 | -38.38 | -50.73 | 21.23 |
| Operating Margin | - | -362.17% | - | - | - | 32.21% |
| Earnings before Tax (EBT) 1 | - | -23.74 | -24.5 | -40.13 | -48.79 | 22.59 |
| Net income 1 | -10.22 | -23.75 | -24.6 | -37.45 | -48.82 | 10.46 |
| Net margin | - | -362.44% | - | - | - | 15.87% |
| EPS 2 | -0.0580 | -0.0960 | -0.0950 | -0.1237 | -0.1605 | 0.0187 |
| Free Cash Flow 1 | - | -13.53 | -27.55 | -33.9 | -49.3 | 42.15 |
| FCF margin | - | -206.39% | - | - | - | 63.96% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 191.89% |
| FCF Conversion (Net income) | - | - | - | - | - | 403.05% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 8/25/21 | 8/24/22 | 8/24/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA 1 | -13.69 | -9.996 | -11.14 | -13.26 |
| EBIT 1 | -13.71 | -10.03 | -11.18 | -13.31 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -13.71 | -10.03 | -11.18 | -13.31 |
| Net income 1 | -13.71 | -10.04 | -11.24 | -13.36 |
| Net margin | - | - | - | - |
| EPS 2 | -0.0570 | -0.0390 | -0.0430 | -0.0520 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/28/22 | 8/24/22 | 2/28/23 | 8/24/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 55.3 | 65 | 131 | 89.2 | 124 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -13.5 | -27.5 | -33.9 | -49.3 | 42.2 |
| ROE (net income / shareholders' equity) | - | -25.8% | -30.5% | -17.5% | -31.9% | 22.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.3700 | 0.2700 | 0.5200 | 0.3400 | 0.4000 |
| Cash Flow per Share 2 | - | - | -0.1100 | -0.1600 | -0.1700 | -0.2000 |
| Capex 1 | - | - | 0.05 | 0.31 | 0.71 | 1.12 |
| Capex / Sales | - | - | - | - | - | 1.7% |
| Announcement Date | 8/25/21 | 8/24/22 | 8/24/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.22
AUD
Average target price
3.867
AUD
Spread / Average Target
-25.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +174.74% | 1.11B | |
| +18.15% | 124B | |
| +18.02% | 111B | |
| -12.75% | 23.17B | |
| +5.07% | 22.94B | |
| -39.94% | 17.42B | |
| -9.86% | 17.42B | |
| -14.97% | 16.9B | |
| +2.80% | 13.71B | |
| +27.39% | 11.82B |
- Stock Market
- Equities
- CU6 Stock
- Financials Clarity Pharmaceuticals Ltd
